Jump to content

Dalteparin sodium: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Addbot (talk | contribs)
m Bot: Migrating 5 interwiki links, now provided by Wikidata on d:q1851701 (Report Errors)
m Added "It is normally adminstered by self-injection."
Line 35: Line 35:
| chemical_formula =
| chemical_formula =
| molecular_weight =
| molecular_weight =
}}'''Dalteparin''' is a [[low molecular weight heparin]]. It is marketed as '''Fragmin''' by [[Pfizer|Pfizer Inc]]. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of [[deep vein thrombosis]] and [[pulmonary embolism]].
}}'''Dalteparin''' is a [[low molecular weight heparin]]. It is marketed as '''Fragmin''' by [[Pfizer|Pfizer Inc]]. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of [[deep vein thrombosis]] and [[pulmonary embolism]]. It is normally adminstered by self-injection.


The CLOT study, published in 2003, showed that in patients with malignancy and acute [[venous thromboembolism]], dalteparin was more effective than [[warfarin]] in reducing the risk of recurrent embolic events.<ref>{{cite journal | author=Lee AY, Levine MN, Baker RI, Bowden C, [[Ajay Kakkar, Baron Kakkar|Kakkar AK]], Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M | title=Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer | journal=N Engl J Med | year=2003 | pages=146–53 | volume=349 | issue=2 | pmid=12853587 | doi=10.1056/NEJMoa025313}}</ref> Dalteparin is not superior to [[unfractionated heparin]] in preventing blood clots.<ref>{{cite journal|author=The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group|title=Dalteparin versus unfractionated heparin in critically ill patients|year=2011|doi=10.1056/NEJMoa1014475}}</ref>
The CLOT study, published in 2003, showed that in patients with malignancy and acute [[venous thromboembolism]], dalteparin was more effective than [[warfarin]] in reducing the risk of recurrent embolic events.<ref>{{cite journal | author=Lee AY, Levine MN, Baker RI, Bowden C, [[Ajay Kakkar, Baron Kakkar|Kakkar AK]], Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M | title=Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer | journal=N Engl J Med | year=2003 | pages=146–53 | volume=349 | issue=2 | pmid=12853587 | doi=10.1056/NEJMoa025313}}</ref> Dalteparin is not superior to [[unfractionated heparin]] in preventing blood clots.<ref>{{cite journal|author=The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group|title=Dalteparin versus unfractionated heparin in critically ill patients|year=2011|doi=10.1056/NEJMoa1014475}}</ref>

Revision as of 10:29, 15 July 2014

Dalteparin sodium
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
KEGG
ECHA InfoCard100.110.590 Edit this at Wikidata

Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism. It is normally adminstered by self-injection.

The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events.[1] Dalteparin is not superior to unfractionated heparin in preventing blood clots.[2]

Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.[3]

References

  1. ^ Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). "Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med. 349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID 12853587.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011). "Dalteparin versus unfractionated heparin in critically ill patients". doi:10.1056/NEJMoa1014475. {{cite journal}}: Cite journal requires |journal= (help)
  3. ^ Douketis J, Cook D, Meade M; et al. (2008). "Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin". Arch Intern Med. 168 (16): 1805–1812. doi:10.1001/archinte.168.16.1805. PMID 18779469. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)